MétaCan
Menu
Back to cohort
Record W3007170690 · doi:10.1002/ana.25709

Robust Markers and Sample Sizes for Multicenter Trials of Huntington Disease

2020· article· en· W3007170690 on OpenAlexfundno aff
P. A. Wijeratne, Eileanoir B. Johnson, Arman Eshaghi, Leon Aksman, Sarah Gregory, Hans J. Johnson, Govinda Poudel, Amrita Mohan, Cristina Sampaio, Nellie Georgiou‐Karistianis, Jane S. Paulsen, Sarah J. Tabrizi, Rachael I. Scahill

Bibliographic record

VenueAnnals of Neurology · 2020
Typearticle
Languageen
FieldNeuroscience
TopicGenetic Neurodegenerative Diseases
Canadian institutionsnot available
FundersNational Center for Research ResourcesNational Institute for Health and Care ResearchNational Institute of Neurological Disorders and StrokeMedical Research CouncilNational Health and Medical Research CouncilHorizon 2020 Framework ProgrammeMedical Research Council CanadaEuropean CommissionCHDI FoundationUniversity College LondonWellcome TrustEngineering and Physical Sciences Research Council
KeywordsSample size determinationMagnetic resonance imagingWhite matterNeuroimagingClinical trialStatistical powerMedicineHuntington's diseaseNuclear medicinePathologyDiseaseRadiologyStatisticsMathematics

Abstract

fetched live from OpenAlex

OBJECTIVE: The identification of sensitive biomarkers is essential to validate therapeutics for Huntington disease (HD). We directly compare structural imaging markers across the largest collective imaging HD dataset to identify a set of imaging markers robust to multicenter variation and to derive upper estimates on sample sizes for clinical trials in HD. METHODS: We used 1 postprocessing pipeline to retrospectively analyze T1-weighted magnetic resonance imaging (MRI) scans from 624 participants at 3 time points, from the PREDICT-HD, TRACK-HD, and IMAGE-HD studies. We used mixed effects models to adjust regional brain volumes for covariates, calculate effect sizes, and simulate possible treatment effects in disease-affected anatomical regions. We used our model to estimate the statistical power of possible treatment effects for anatomical regions and clinical markers. RESULTS: We identified a set of common anatomical regions that have similarly large standardized effect sizes (>0.5) between healthy control and premanifest HD (PreHD) groups. These included subcortical, white matter, and cortical regions and nonventricular cerebrospinal fluid (CSF). We also observed a consistent spatial distribution of effect size by region across the whole brain. We found that multicenter studies were necessary to capture treatment effect variance; for a 20% treatment effect, power of >80% was achieved for the caudate (n = 661), pallidum (n = 687), and nonventricular CSF (n = 939), and, crucially, these imaging markers provided greater power than standard clinical markers. INTERPRETATION: Our findings provide the first cross-study validation of structural imaging markers in HD, supporting the use of these measurements as endpoints for both observational studies and clinical trials. ANN NEUROL 2020;87:751-762.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.315
metaresearch head score (Gemma)0.584
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Simulation or modeling · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.315
Threshold uncertainty score0.844

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.3150.584
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0040.006
Bibliometrics0.0030.003
Science and technology studies0.0010.005
Scholarly communication0.0040.004
Open science0.0030.005
Research integrity0.0040.004
Insufficient payload (model declined to judge)0.0050.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.244
GPT teacher head0.357
Teacher spread0.113 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

Study designSimulation or modeling
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations29
Published2020
Admission routes1
Has abstractyes

Explore more

Same venueAnnals of NeurologySame topicGenetic Neurodegenerative DiseasesFrench-language works237,207